期刊
LANCET INFECTIOUS DISEASES
卷 11, 期 7, 页码 557-570出版社
ELSEVIER SCI LTD
DOI: 10.1016/S1473-3099(11)70007-X
关键词
-
资金
- GSK Biologicals
- Sanofi Pasteur MSD
- Wyeth
- GSK
- PVD's
- University of Antwerp
- Novartis
- Sanofi Pasteur
Although the introduction of universal pertussis immunisation in infants has greatly reduced the number of reported cases in infants and young children, disease incidence has been increasing in adolescents and adults in recent years. This changing epidemiological pattern is probably largely attributable to waning immunity after natural infection or vaccination. Furthermore, improved diagnostic testing, active surveillance, changes in disease susceptibility, vaccine characteristics, and increased awareness of the disease might also be contributing factors. Susceptibility to pertussis in adolescents and adults results not only in direct morbidity in these age groups, but also poses a transmission risk to susceptible non-immune infants who are often too young to be vaccinated. Because vaccination schedules vary across Europe, we review the pertussis situation in this region and propose considerations for use of pertussis booster vaccinations at different ages to reduce individual morbidity and transmission from present rates and increase herd protection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据